Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
NEW HAVEN, Conn. April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA , from May 17-22 . The presentation will take place on May 19 th ATS 2024 International Conference May 17-22, 2024 San Diego, CA Session : A104: Advances in the Diagnosis and Treatment of ILD Abstract Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis Presentation May 19 3:00 p.m. - 4:15 p.m. PT Location San Diego Convention Center, Room 33A-C (Upper Level) Presenter Jacky Smith, MB, ChB FRCP PhD , Professor of Respiratory Medicine at the University of Manch
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferencePR Newswire
- Trevi Therapeutics to Participate in Upcoming April Events [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics to Participate in Upcoming April EventsPR Newswire
- Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 3/20/24 - Beat
TRVI
Sec Filings
- 4/29/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TRVI's page on the SEC website